Assenagon Asset Management S.A. acquired a new stake in Qiagen NV (NYSE:QGEN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 5,681 shares of the company’s stock, valued at approximately $243,000.
Several other hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Qiagen in the 4th quarter worth approximately $111,086,000. Magnetar Financial LLC boosted its holdings in shares of Qiagen by 24,274.8% in the 1st quarter. Magnetar Financial LLC now owns 2,495,244 shares of the company’s stock worth $100,769,000 after acquiring an additional 2,485,007 shares in the last quarter. ARP Americas LP acquired a new position in shares of Qiagen in the 1st quarter worth approximately $86,280,000. Canada Pension Plan Investment Board boosted its holdings in shares of Qiagen by 1,343.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 1,924,555 shares of the company’s stock worth $77,310,000 after acquiring an additional 1,791,242 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Qiagen by 97.2% in the 1st quarter. Victory Capital Management Inc. now owns 3,602,300 shares of the company’s stock worth $149,856,000 after acquiring an additional 1,775,235 shares in the last quarter. Institutional investors own 60.21% of the company’s stock.
Shares of Qiagen stock opened at $49.45 on Friday. The firm has a fifty day moving average of $45.00 and a two-hundred day moving average of $40.78. The stock has a market capitalization of $11.26 billion, a price-to-earnings ratio of -309.06, a PEG ratio of 1.08 and a beta of 0.32. Qiagen NV has a 52 week low of $25.04 and a 52 week high of $50.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.41 and a current ratio of 1.58.
Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.07. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The business had revenue of $372.10 million during the quarter, compared to analysts’ expectations of $342.71 million. During the same quarter in the prior year, the company earned $0.27 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, research analysts forecast that Qiagen NV will post 2.09 EPS for the current fiscal year.
QGEN has been the topic of several recent analyst reports. Warburg Research reissued a “neutral” rating on shares of Qiagen in a report on Tuesday, June 23rd. DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a report on Monday, July 20th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $37.33.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: Preferred Stock
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.